Skip to main content
SpringerLink
Log in

Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system

  • Preclinical
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

A human tumor cloning system was used to assess the cytotoxicity of adriamycin, mitoxantrone and bisantrene at concentrations that are equitoxic in man. There were 989 specimens evaluable for drug sensitivity analysis. Overall, adriamycin showed in vitro cytotoxicity (≥ 50% decrease in tumor colony forming units) 14% of the time; mitoxantrone, 21% of the time; and bisantrene, 31% of the time. Three hundred ninety-nine of these evaluable specimens were simultaneously tested against more than one of the agents, providing 631 two-way drug comparisons. For these comparisons, there was lack of co-resistance 27–34% of the time, with mitoxantrone being more active than adriamycin (p < .05) and bisantrene being more active than adriamycin (p < .01) or mitoxantrone (p < .01). These data suggest that comparative and sequential clinical use of these agents should be investigated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Alberts DS, Chen HSG, Salmon SE: In vitro drug assay: pharmacologic considerations. In Salmon SE (ed): Cloning of Human Tumor Stem Cells. Alan R. Liss, New York, 1980, pp. 197–207

    Google Scholar 

  2. Blum RH, Carter SK: Adriamycin — a new anticancer drug with significant clinical activity. Ann Intern Med 80:249–259, 1974

    Google Scholar 

  3. Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE: Antitumor activity of CL216.942: 9,10-Anthracenedi-carboxaldehyde bis ((4,5 dihydro-1H-imidazol-2-yl)-hydrazone)dihydrochloride. Abstracts of the 20th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1980 (Abstract 23)

  4. Hamburger AW, Salmon SE: Primary bioassay of human myeloma stem cells. J Clin Invest 60:846–854, 1977

    Google Scholar 

  5. Hamburger AW, Salmon SE: Primary bioassay of human tumor stem cells. Science 197:461–463, 1977

    Google Scholar 

  6. Hamburger AW, Salmon SE, Kim MB, Trent JM, Soehnlen BJ, Alberts DS, Schmidt HJ: Direct cloning of human ovarian carcinoma cells in agar. Cancer Res 38:3438–3444, 1978

    Google Scholar 

  7. Johnson RK, Zee-Cheng RKY, Lee WW, Acton FM, Henry DW, Cheng CC: Experimental antitumor activity of aminoanthraquinones. Cancer Treat Rep 63:425–539, 1979

    Google Scholar 

  8. Pike BL, Robinson WA: Human bone marrow colony growth in agar-gel. J Cell Physiol 76:77–81, 1970

    Google Scholar 

  9. Salmon SE, Alberts DS, Meyskens FL, Durie BGM, Jones SE, Soehnlen BJ, Young L, Chen HSG, Moon TE: Clinical correlations of in vitro drug sensitivity. In Salmon SE (ed): Cloning of Human Tumor Stem Cells. Alan R. Liss, New York, 1980, pp. 223–245

    Google Scholar 

  10. Van Echo DA, Shulman PN, Ferrari A, Budman D, Markus SD, Wiernik PH: A phase II trial of Mitoxantrone (DHAD, NSC 301739) in adult acute leukemia. Proc Am Soc Clin Oncol 1:132, 1982

    Google Scholar 

  11. Venditti JM: Preclinical drug development: rationale and methods. Sem Oncol 8:349–361, 1981

    Google Scholar 

  12. Von Hoff DD, Pollard E, Kuhn J, Murray E, Coltman CA Jr; Phase I clinical investigation of 1,4-dihydroxy-5,8-bis ((2-(2-hydroxyethylamino)ethyl)amino)-9,10 anthracenedione dihydrochloride (NSC 301739), a new anthracenedione. Cancer Res 40:1516–1518, 1980

    Google Scholar 

  13. Von Hoff DD, Myers JW, Kuhn J, Sandbach J, Pocelinko R, Clark G, Coltman CJR: Phase I clinical investigation of 9–10 anthracenedicarboxaldehyde bis ((4,5-dihydro-1H-imidazol-2-yl)hydrazone) dihydrochloride (CL216,942). Cancer Res 41:3118–3121, 1981

    Google Scholar 

  14. Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R: Association between human tumor colony forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med 70:1027–1032, 1981

    Google Scholar 

  15. Wallace RE, Murdock KC, Angier RB, Durr FE: Activity of a novel anthracenedione, 1,4-dihydroxy-5,8-bis 2-[(2-hydroxyethyl)aminoethyl amino-9,-10 anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:1570–1574, 1979

    Google Scholar 

  16. Yap HY, Blumenschien GR, Schell FC, Buzdar AU, Valdivieso M, Bodey GP: Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Int Med 95:694–697, 1981

    Google Scholar 

  17. Zee-Cheng RKY, Cheng CC: Antineoplastic agents. Structure activity relationship study of bis (substituted aminoalkylamino)anthraquinones. J Med Chem 21:291–294, 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Brooke Army Medical Center, 78234, Fort Sam Houston, TX, U.S.A.

    John D. Cowan M.D.

  2. University of Texas Health Science Center, 78284, San Antonio, TX, U.S.A.

    Daniel D. Von Hoff & Gary M. Clark

Authors
  1. John D. Cowan M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel D. Von Hoff
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gary M. Clark
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cowan, J.D., Von Hoff, D.D. & Clark, G.M. Comparative cytotoxicity of adriamycin, mitoxantrone and bisantrene as measured by a human tumor cloning system. Invest New Drugs 1, 139–144 (1983). https://doi.org/10.1007/BF00172072

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00172072

Key words

Search

Navigation